Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors
Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors
About this item
Full title
Author / Creator
Strosberg, J. , El-Haddad, G. , Wolin, E. , Hendifar, A. , Yao, J. , Chasen, B. , Mittra, E. , Kunz, P. L. , Kulke, M. H. , Jacene, H. , Bushnell, D. , O'Dorisio, T. M. , Baum, R. P. , Kulkarni, H. R. , Caplin, M. , Lebtahi, R. , Hobday, T. , Delpassand, E. , Van Cutsem, E. , Benson, A. , Srirajaskanthan, R. , Pavel, M. , Mora, J. , Berlin, J. , Grande, E. , Reed, N. , Seregni, E. , Öberg, Kjell , Sierra, M. Lopera , Santoro, P. , Thevenet, T. , Erion, J. L. , Ruszniewski, P. , Kwekkeboom, D. and Krenning, E.
Journal title
Language
English
Formats
More information
Scope and Contents
Contents
BACKGROUND Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (Lu-177)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive...
Alternative Titles
Full title
Phase 3 Trial of Lu-177-Dotatate for Midgut Neuroendocrine Tumors
Authors, Artists and Contributors
Author / Creator
El-Haddad, G.
Wolin, E.
Hendifar, A.
Yao, J.
Chasen, B.
Mittra, E.
Kunz, P. L.
Kulke, M. H.
Jacene, H.
Bushnell, D.
O'Dorisio, T. M.
Baum, R. P.
Kulkarni, H. R.
Caplin, M.
Lebtahi, R.
Hobday, T.
Delpassand, E.
Van Cutsem, E.
Benson, A.
Srirajaskanthan, R.
Pavel, M.
Mora, J.
Berlin, J.
Grande, E.
Reed, N.
Seregni, E.
Öberg, Kjell
Sierra, M. Lopera
Santoro, P.
Thevenet, T.
Erion, J. L.
Ruszniewski, P.
Kwekkeboom, D.
Krenning, E.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_DiVA_org_uu_315816
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_DiVA_org_uu_315816
Other Identifiers
ISSN
1533-4406,0028-4793
DOI
10.1056/NEJMoa1607427
